Putting nature back into medicine.

Evithé Biotechnology is a bio-pharmaceutical company that develops novel, patented botanical and multi-target pharmaceutical prescription drugs from ginger rhizomes.

Inflammatory disease are the number 1 cause of death and disability worldwide.

Evithé Biotechnology is inspired by nature and has a pipeline of botanical and pharmaceutical prescription drugs that can address a range of disease targets to get to the root of inflammatory disorders such as Rheumatoid Arthritis, Alzheimer’s disease and sepsis.

Botanical drugs are prescription medicines that are intended to cure, mitigate, treat or prevent diseases.

Consumer surveys identified that 78% of patients prefer a Botanical Drug over a synthetic chemical. Botanical drugs have a short pathway to market and are available on prescription in the US, Europe & Asia.

Watch an in-depth interview with Cynthia's journey in founding Evithé and her mission of commercially developing complex botanicals.

The team

Cynthia Hunefeld

Founder & CEO

Mrs Hunefeld dedicated her life, work and studies in ethnobotany, plant medicine, Post graduate Diploma in clinical research and Masters in Innovation & Commercialisation to the development of botanical medicines.

Alan Sutton

Chief Science Officer

Alan provided contract bioanalysis on clinical trial samples for several major pharmaceutical companies. He joined GW Pharmaceuticals in 2001, forming and managing the analytical chemistry department developing methodologies for characterisation of complex botanical materials. 

Kylie Watt


Kylie Watt is a qualified Chartered Accountant with a Bachelor of Commerce degree in accounting, finance and information systems. Over the last 15 years she has gained experience in various accounting and finance roles across the areas of audit, business advisory, financial analysis, and commercial management. Kylie brings with her a combination of strong technical accounting knowledge and proficiency in financial management and analysis.

Dr Sebastian Ceron

Operations Assistant

Sebastian completed his training as a medical doctor, gaining clinical and research experience in international institutions. In 2024 he completed his Masters degree in Clinical Immunology at Victoria University to understand and apply the concepts of the immune system into clinical research.

John Clough


Val Hooper


Allan MacDonald


Allan is an experienced director active in international markets for over 30 years. After successful careers with Mobil and Sony, he helped to establish the CSI (food) group of companies within New Zealand.

He has developed an extensive skill set through his involvement in opening and building international markets and scaling companies. With his skill in developing enduring relationships with clients, suppliers and other stakeholders – including overseeing complex contract negotiations and helping to guide innovative and groundbreaking Product development programs, he brings a wealth of experience to the Board to help with Evithé’s rapid growth.

Lorraine Thomson

Independent Director

A Master of Business Administration from New Zealand’s leading business school at the University of Auckland, Lorraine has a particular focus on innovation and strategic growth. She is an ArcAngel investor and an experienced company director on five boards, including the Gillies McIndoe Research Institute.

She is a former award-winning journalist, editor, publisher and author. Titles she has edited include New Zealand Pharmacy journal and also sub-editor of The National Business Review.

Dr Jane Calvert

Legal Advisor

Registered Trans-Tasman patent attorney with a PhD in Organic Chemistry. Jane has unique knowledge of both biotechnology and botanical drug development as well as the requirements for innovation and commercialisation pathways.

She brings a wealth of practical experience in building a companies intellectual property portfolio from start-up to large corporate from laboratory to public listing.

Watch Evithé's founder Cynthia Hunefeld talk about the story behind Evithé.

Evithé biotechnology is inspired by the way that plants have evolved over thousands of years and has found a way to harness their actions into novel botanical drugs with the intention to cure, mitigate, treat or prevent disease in humans.

The Botanical Drug Development Project won multiple awards including:

Contact us

At our current stage we welcome interest from investors, as well as those that have a desire to follow our developments.

You can connect with Evithé through our digital channels in order to stay up to date.

Evithé, life is in our name.

Evithé [eɪ Viː teɪ]

An early European derivative of the Hebrew Evia, meaning 'source (or breath) of life'.

©2024 Evithé Biotechnology